© 2015 The British Infection Association. Capsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the licensure of the 4CMenB vaccine and discusses recommendations for its use.

Original publication

DOI

10.1016/j.jinf.2015.04.021

Type

Journal article

Journal

Journal of Infection

Publication Date

01/01/2015

Volume

71

Pages

S15 - S20